title: First-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejection.
abstract: TOL101 is a murine IgM mAb targeting the αβ TCR. Unlike other T cell targets, the αβ TCR has no known intracellular signaling domains and may provide a nonmitogenic target for T cell inactivation. We report the 6-month Phase 2 trial data testing TOL101 in kidney transplantation. The study was designed to identify a dose that resulted in significant CD3 T cell modulation (<25 T cell/mm(3) ), to examine the safety and tolerability of TOL101 and to obtain preliminary efficacy information. Thirty-six patients were enrolled and given 5-10 daily doses of TOL101; 33 patients completed dosing, while three discontinued after two doses due to a self-limiting urticarial rash. Infusion adjustments, antihistamines, steroids and dose escalation of TOL101 reduced the incidence of the rash. Doses of TOL101 above 28 mg resulted in prolonged CD3 modulation, with rapid recovery observed 7 days after therapy cessation. There were no cases of patient or graft loss. Few significant adverse events were reported, with one nosocomial pneumonia. There were five biopsy-confirmed acute cellular rejections (13.9%); however, no donor-specific antibodies were detected. Overall TOL101 was well-tolerated, supporting continued clinical development using the dose escalating 21-28-42-42-42 mg regimen.
authors.affiliation: Glickman Urology and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH.
authors.forename: S M
authors.initials: SM
authors.lastname: Flechner
authors.forename: S
authors.initials: S
authors.lastname: Mulgoankar
authors.forename: L B
authors.initials: LB
authors.lastname: Melton
authors.forename: T H
authors.initials: TH
authors.lastname: Waid
authors.forename: A
authors.initials: A
authors.lastname: Agarwal
authors.forename: S D
authors.initials: SD
authors.lastname: Miller
authors.forename: F
authors.initials: F
authors.lastname: Fokta
authors.forename: M T
authors.initials: MT
authors.lastname: Getts
authors.forename: T J
authors.initials: TJ
authors.lastname: Frederick
authors.forename: J J
authors.initials: JJ
authors.lastname: Herrman
authors.forename: J P
authors.initials: JP
authors.lastname: Puisis
authors.forename: L
authors.initials: L
authors.lastname: O'Toole
authors.forename: R
authors.initials: R
authors.lastname: Sung
authors.forename: F
authors.initials: F
authors.lastname: Shihab
authors.forename: A C
authors.initials: AC
authors.lastname: Wiseman
authors.forename: D R
authors.initials: DR
authors.lastname: Getts
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008297:Male; D008875:Middle Aged
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C000594305:TOL-101
keywords: Acute rejection; induction; kidney transplantation
references.citation: Curr Opin Organ Transplant. 2009 Aug;14(4):419-25
references.pmid: 19444105
references.citation: Transplant Proc. 1997 Nov;29(7A):24S-26S
references.pmid: 9366923
references.citation: J Am Soc Nephrol. 1998 Aug;9(8):1521-5
references.pmid: 9697676
references.citation: BioDrugs. 2005;19(1):39-46
references.pmid: 15691216
references.citation: Onkologie. 1988 Feb;11(1):56-8
references.pmid: 3283628
references.citation: Transplantation. 2009 Apr 27;87(8 Suppl):S1-6
references.pmid: 19384179
references.citation: Transplantation. 2003 Dec 27;76(12):1662-8
references.pmid: 14688512
references.citation: Ann Otol Rhinol Laryngol. 2006 Jan;115(1):74-80
references.pmid: 16466103
references.citation: Immunotherapy. 2011 Jul;3(7):853-70
references.pmid: 21751954
references.citation: N Engl J Med. 2010 Oct 7;363(15):1451-62
references.pmid: 20925547
references.citation: Am J Transplant. 2005 Oct;5(10):2539-48
references.pmid: 16162205
references.citation: Transplantation. 2004 Jan 27;77(2):166-76
references.pmid: 14742976
references.citation: N Engl J Med. 2005 Aug 25;353(8):770-81
references.pmid: 16120857
references.citation: J Clin Invest. 1978 Mar;61(3):703-7
references.pmid: 305923
references.citation: Am J Transplant. 2007 Jul;7(7):1832-42
references.pmid: 17564638
references.citation: Drugs. 2012 Mar 26;72(5):671-83
references.pmid: 22439670
references.citation: Lancet. 1997 Oct 25;350(9086):1193-8
references.pmid: 9652559
references.citation: Eur J Immunol. 1991 May;21(5):1163-9
references.pmid: 1828030
references.citation: Transplantation. 2000 Jun 15;69(11):2374-81
references.pmid: 10868643
references.citation: Mol Immunol. 2008 Feb;45(3):583-98
references.pmid: 17869342
references.citation: Immunology. 1994 Jan;81(1):1-7
references.pmid: 7510661
references.citation: MAbs. 2010 Nov-Dec;2(6):682-94
references.pmid: 20935511
references.citation: Transplantation. 2010 Dec 27;90(12):1511-5
references.pmid: 21057388
references.citation: N Engl J Med. 2004 Dec 23;351(26):2715-29
references.pmid: 15616206
references.citation: Transplantation. 1992 Jan;53(1):80-6
references.pmid: 1531095
references.citation: N Engl J Med. 2011 May 19;364(20):1909-19
references.pmid: 21591943
references.citation: N Engl J Med. 2006 Nov 9;355(19):1967-77
references.pmid: 17093248
references.citation: Transplantation. 1997 Jul 27;64(2):274-81
references.pmid: 9256187